Regeneron posts Q3 2026 earnings beat, driven by Dupixent and $1 billion Sanofi upfront payment
Regeneron Pharmaceuticals reported third‑quarter 2026 revenue of $5.12 billion, up 36% year‑over‑year, and non‑GAAP earnings per share of $20.07, beating consensus estimates. The results were powered by record sales of Dupixent and a $1 billion upfront payment from Sanofi for an expanded collaboration on long‑acting antibodies. The company also raised its full‑year gross‑margin guidance and increased its R&D spending outlook.
Why it matters
The earnings beat and higher guidance suggest stronger cash flow and profitability for the remainder of 2026, which could support a higher share price and attract further investor interest. The $1 billion upfront payment adds immediate revenue and signals continued partnership strength with Sanofi.
Key facts
- 1Q3 2026 revenue was $5.12 billion, a 36% increase from the prior year. stocktitan.net
- 2Non‑GAAP EPS was $20.07, a 70% rise year‑over‑year. stocktitan.net
- 3Regeneron received a $1.0 billion upfront payment from Sanofi for an expanded collaboration. stocktitan.net
- 4Dupixent global net sales grew 35% to $6.5 billion. stocktitan.net
- 5EYLEA HD U.S. net sales increased 62% to $699 million. stocktitan.net
- 6Full‑year 2026 gross‑margin guidance was raised to about 86% on a non‑GAAP basis. quiverquant.com
Summary written by AlphAI AI Desk from 20 of 24 sources. Not investment advice. Figures are as stated by the linked sources.